Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a coated catheter stop deadly ICU infections?

NCT ID NCT05959018

Prevention Sponsor: University of Malaya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a catheter coated with antimicrobial medicine could prevent serious bloodstream infections in intensive care patients. Researchers compared the coated catheter to a standard one in 110 adults in a Malaysian hospital ICU. They looked at infection rates, length of hospital stay, and costs to see if the special catheter is worth the extra expense.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Antimicrobial-impregnated central venous catheter (Arrowg+ard Blue Plus®)
What this could lead to
If effective, this could show that antimicrobial-coated catheters reduce dangerous bloodstream infections and save healthcare costs in ICUs.
What could go wrong
This is a small, single-center study (110 participants) that is already completed. Results may not apply to other hospitals or countries, and the catheters are more expensive, so cost-effectiveness is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Jan 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years old and above who are admitted to the ICU of UMMC during the study period * Patients who require a CVC during ICU stay Exclusion Criteria: * Patients who refuse to participate in the study * Patients with known hypersensitivity reaction to CVC materials * Patients with pre-existing diagnosis of CLABSI upon admission to the ICU * Patients with pre-existing bloodstream infection upon admission to the ICU * Patients with a pre-existing CVC, where sterility during placement may be compromised (e.g. in an emergency situation) * Patients with indwelling CVC less than 48 hours * Patients who had poor compliance to catheter bundle care during CVC handling throughout the indwelling catheter period * Patients who require \> 1 CVC or other central venous access

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clabsi - central line associated bloodstream infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clabsi - central line associated bloodstream infection

Contacts and locations

Locations

  • Universiti of Malaya Medical Centre

    Kuala Lumpur, Kuala Lumpur, 59100, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.